Privia Health Group (PRVA) Financials

$25.99 +0.11 (+0.43%)

Closing price 10/24/2025 04:00 PM Eastern

Extended Trading

$26.22 +0.24 (+0.90%)

As of 10/24/2025 07:21 PM Eastern

Annual Income Statements for Privia Health Group

This table shows Privia Health Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	8.24	31	-188	-8.59	23	14
Consolidated Net Income / (Loss)	7.95	31	-191	-12	21	17
Net Income / (Loss) Continuing Operations	7.95	31	-191	-12	21	17
Total Pre-Tax Income	9.15	23	-219	-19	29	28
Total Operating Income	16	25	-217	-19	21	17
Total Gross Profit	691	712	791	1,186	1,460	1,509
Total Revenue	786	817	966	1,357	1,658	1,736
Operating Revenue	786	817	966	1,357	1,658	1,736
Total Cost of Revenue	95	105	175	171	198	227
Operating Cost of Revenue	95	105	175	171	198	227
Total Operating Expenses	675	687	1,009	1,205	1,439	1,492
Selling, General & Admin Expense	42	44	256	130	110	126
Marketing Expense	9.16	11	23	20	25	26
Depreciation Expense	1.43	1.84	2.46	4.57	6.53	7.27
Other Operating Expenses / (Income)	623	629	728	1,051	1,299	1,333
Total Other Income / (Expense), net	-6.91	-1.92	-1.07	0.54	8.37	11
Other Income / (Expense), net	-	-	-	0.54	8.37	11
Income Tax Expense	1.21	-7.44	-28	-6.52	7.99	11
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.30	-0.34	-2.42	-3.48	-2.05	2.66
Basic Earnings per Share	$0.09	$0.33	($1.83)	($0.08)	$0.20	$0.12
Weighted Average Basic Shares Outstanding	95.93M	95.95M	102.95M	110.70M	116.73M	119.40M
Diluted Earnings per Share	$0.09	$0.33	($1.83)	($0.08)	$0.19	$0.11
Weighted Average Diluted Shares Outstanding	95.93M	95.95M	102.95M	110.70M	124.69M	125.61M
Weighted Average Basic & Diluted Shares Outstanding	-	-	108.17M	115.00M	118.57M	120.51M

This table shows Privia Health Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	1.62	18	7.32	7.27	5.64	2.84	2.98	3.47	3.54	4.40	4.22
Consolidated Net Income / (Loss)	0.56	17	6.40	6.36	5.94	2.32	3.06	4.64	3.98	5.37	6.05
Net Income / (Loss) Continuing Operations	0.56	17	6.40	6.36	5.94	2.32	3.06	4.64	3.98	5.37	6.05
Total Pre-Tax Income	-4.29	3.40	8.53	7.80	8.43	4.27	3.81	8.06	7.98	8.02	8.15
Total Operating Income	-4.57	2.25	6.71	6.98	5.54	1.42	0.82	5.10	5.81	5.25	5.22
Total Gross Profit	299	321	342	363	367	388	361	365	382	401	421
Total Revenue	343	364	386	413	417	441	415	422	438	461	480
Operating Revenue	343	364	386	413	417	441	415	422	438	461	480
Total Cost of Revenue	44	43	45	50	50	52	54	57	56	60	60
Operating Cost of Revenue	44	43	45	50	50	52	54	57	56	60	60
Total Operating Expenses	304	319	335	356	361	387	360	360	376	396	415
Selling, General & Admin Expense	32	28	26	27	27	30	32	29	31	34	32
Marketing Expense	5.09	5.17	5.29	5.96	7.24	6.25	6.09	6.85	7.05	6.46	6.92
Depreciation Expense	1.15	1.14	1.34	1.69	1.73	1.77	1.82	1.82	1.80	1.83	1.90
Other Operating Expenses / (Income)	265	284	302	322	325	349	320	323	337	353	375
Total Other Income / (Expense), net	0.29	1.15	1.81	0.82	2.89	2.85	2.98	2.97	2.16	2.77	2.93
Other Income / (Expense), net	-	-	-	0.82	2.89	-	-	2.97	2.16	-	2.93
Income Tax Expense	-4.85	-13	2.13	1.44	2.49	1.94	0.75	3.42	4.00	2.66	2.10
Net Income / (Loss) Attributable to Noncontrolling Interest	-1.07	-0.93	-0.92	-0.91	0.30	-0.51	0.07	1.18	0.44	0.97	1.83
Basic Earnings per Share	$0.01	$0.17	$0.06	$0.06	$0.05	$0.03	$0.03	$0.03	$0.03	$0.03	$0.03
Weighted Average Basic Shares Outstanding	111.59M	110.70M	115.01M	116.16M	117.60M	116.73M	118.51M	119.30M	119.66M	119.40M	120.62M
Diluted Earnings per Share	$0.01	$0.17	$0.06	$0.06	$0.05	$0.02	$0.02	$0.03	$0.03	$0.03	$0.03
Weighted Average Diluted Shares Outstanding	124.85M	110.70M	124.33M	124.57M	124.92M	124.69M	125.05M	125.32M	125.75M	125.61M	127.75M
Weighted Average Basic & Diluted Shares Outstanding	114.30M	115.00M	115.66M	117.36M	118.06M	118.57M	119.32M	119.56M	120.00M	120.51M	121.92M

This table details how cash moves in and out of Privia Health Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	7.78	38	236	27	42	102
Net Cash From Operating Activities	24	39	55	47	81	109
Net Cash From Continuing Operating Activities	24	39	55	47	81	109
Net Income / (Loss) Continuing Operations	7.95	31	-191	-12	21	17
Consolidated Net Income / (Loss)	7.95	31	-191	-12	21	17
Depreciation Expense	0.78	1.19	1.15	1.22	1.17	1.10
Amortization Expense	0.98	0.78	1.47	4.04	5.36	6.16
Non-Cash Adjustments To Reconcile Net Income	0.21	0.48	267	67	37	57
Changes in Operating Assets and Liabilities, net	14	5.54	-24	-13	16	28
Net Cash From Investing Activities	-5.71	-0.38	-33	-0.10	-43	-12
Net Cash From Continuing Investing Activities	-5.71	-0.38	-33	-0.10	-43	-12
Acquisitions	0.00	0.00	-32	0.00	-43	-6.96
Other Investing Activities, net	-	-	-	-0.10	-0.11	-5.02
Net Cash From Financing Activities	-11	-0.77	214	-20	3.71	4.33
Net Cash From Continuing Financing Activities	-11	-0.77	214	-20	3.71	4.33
Repayment of Debt	-46	-11	-1.16	-33	0.00	0.00
Payment of Dividends	-	-	0.00	0.00	-5.69	0.00
Issuance of Common Equity	0.00	0.00	224	0.13	0.66	1.65
Other Financing Activities, net	0.00	0.11	3.83	13	8.74	2.68
Cash Interest Paid	9.20	1.93	0.89	0.71	0.04	0.29
Cash Income Taxes Paid	0.32	0.38	0.50	0.31	1.04	3.76

This table details how cash moves in and out of Privia Health Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	25	31	-37	6.72	12	59	-38	36	35	69	-22
Net Cash From Operating Activities	16	29	-13	7.61	22	64	-33	34	33	75	-24
Net Cash From Continuing Operating Activities	16	29	-13	7.61	22	64	-33	34	33	75	-24
Net Income / (Loss) Continuing Operations	0.56	17	6.40	6.36	5.94	2.32	3.06	4.64	3.98	5.37	6.05
Consolidated Net Income / (Loss)	0.56	17	6.40	6.36	5.94	2.32	3.06	4.64	3.98	5.37	6.05
Depreciation Expense	0.31	0.29	0.29	0.29	0.30	0.30	0.29	0.29	0.29	0.23	0.23
Amortization Expense	0.84	0.84	1.05	1.40	1.43	1.48	1.53	1.53	1.51	1.60	1.67
Non-Cash Adjustments To Reconcile Net Income	15	9.18	4.69	9.94	8.29	14	12	14	15	15	18
Changes in Operating Assets and Liabilities, net	-0.40	2.00	-26	-10	6.50	46	-50	14	12	52	-50
Net Cash From Investing Activities	-0.02	-0.02	-25	-0.07	-13	-5.02	-5.71	-	-	-6.27	0.00
Net Cash From Continuing Investing Activities	-0.02	-0.02	-25	-0.07	-13	-5.02	-5.71	-	-	-6.27	0.00
Acquisitions	-	-	-25	-	-13	-5.00	-0.71	-	-	-6.25	0.00
Other Investing Activities, net	-	-	0.00	-0.07	-0.02	-0.02	-5.01	-	-	-0.02	0.00
Net Cash From Financing Activities	8.57	1.96	1.48	-0.82	3.01	0.04	0.48	1.75	1.49	0.62	2.24
Net Cash From Continuing Financing Activities	8.57	1.96	1.48	-0.82	3.01	0.04	0.48	1.75	1.49	0.62	2.24
Other Financing Activities, net	8.57	1.96	1.48	4.31	3.01	-0.05	0.48	0.75	0.84	0.62	2.24
Cash Interest Paid	0.03	0.03	0.02	0.04	-0.02	-	0.09	0.06	0.07	0.06	0.00
Cash Income Taxes Paid	0.02	0.04	-0.01	0.60	0.42	0.02	-0.23	3.11	0.64	0.23	-0.31

This table presents Privia Health Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	329	686	793	1,000	1,136
Total Current Assets	190	447	552	701	835
Cash & Equivalents	85	321	348	390	491
Accounts Receivable	99	117	190	291	316
Prepaid Expenses	6.33	8.70	14	21	27
Plant, Property, & Equipment, net	4.81	4.50	3.39	2.33	1.24
Total Noncurrent Assets	134	235	237	297	300
Goodwill	119	128	127	139	142
Intangible Assets	5.98	60	57	108	110
Noncurrent Deferred & Refundable Income Taxes	4.95	33	40	35	26
Other Noncurrent Operating Assets	4.48	14	13	15	22
Total Liabilities & Shareholders' Equity	329	686	793	1,000	1,136
Total Liabilities	185	236	274	393	452
Total Current Liabilities	147	190	264	387	449
Accounts Payable	39	46	53	58	82
Other Current Liabilities	107	144	211	329	367
Total Noncurrent Liabilities	38	46	9.49	5.56	3.19
Other Noncurrent Operating Liabilities	5.60	14	9.49	5.56	3.19
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	144	450	519	607	683
Total Preferred & Common Equity	147	427	499	561	635
Total Common Equity	147	427	499	561	635
Common Stock	167	635	716	755	814
Retained Earnings	-20	-208	-217	-194	-179
Noncontrolling Interest	-3.10	23	20	46	48

This table presents Privia Health Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	808	875	938	992	1,032	1,078	1,146	1,184
Total Current Assets	580	589	654	698	728	780	854	886
Cash & Equivalents	317	311	318	330	351	387	422	469
Accounts Receivable	246	261	320	350	346	370	409	389
Prepaid Expenses	16	17	16	17	31	22	23	28
Plant, Property, & Equipment, net	3.66	3.10	2.88	2.60	2.04	1.75	1.46	1.01
Total Noncurrent Assets	224	283	281	292	301	296	290	296
Goodwill	127	135	135	136	139	139	139	142
Intangible Assets	58	98	96	107	106	105	103	108
Noncurrent Deferred & Refundable Income Taxes	27	39	37	35	34	31	28	25
Other Noncurrent Operating Assets	12	12	12	14	22	21	20	22
Total Liabilities & Shareholders' Equity	808	875	938	992	1,032	1,078	1,146	1,184
Total Liabilities	317	319	366	401	409	434	483	474
Total Current Liabilities	305	310	358	394	404	430	479	471
Accounts Payable	47	46	49	54	51	61	66	68
Other Current Liabilities	257	263	310	340	353	369	414	403
Total Noncurrent Liabilities	12	9.13	7.82	7.08	4.96	4.42	3.91	3.20
Other Noncurrent Operating Liabilities	12	9.13	7.82	7.08	4.96	4.42	3.91	3.20
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	491	557	571	591	623	644	662	710
Total Preferred & Common Equity	470	513	525	545	577	595	615	659
Total Common Equity	470	513	525	545	577	595	615	659
Common Stock	705	723	727	741	767	783	799	834
Retained Earnings	-234	-209	-202	-196	-191	-187	-184	-175
Noncontrolling Interest	21	43	46	46	46	48	47	50

This table displays calculated financial ratios and metrics derived from Privia Health Group's official financial filings.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	3.91%	18.25%	40.41%	22.19%	4.74%
EBITDA Growth	0.00%	53.44%	-885.60%	93.80%	366.88%	-1.17%
EBIT Growth	0.00%	58.01%	-956.72%	91.46%	256.19%	-3.97%
NOPAT Growth	0.00%	139.74%	-555.31%	91.21%	211.78%	-30.59%
Net Income Growth	0.00%	288.97%	-716.91%	93.67%	274.30%	-18.95%
EPS Growth	0.00%	266.67%	-654.55%	95.63%	337.50%	-42.11%
Operating Cash Flow Growth	0.00%	59.66%	41.57%	-14.28%	71.17%	35.28%
Free Cash Flow Firm Growth	0.00%	0.00%	-274.17%	89.95%	-43.02%	212.89%
Invested Capital Growth	0.00%	0.00%	74.98%	5.48%	27.37%	-11.74%
Revenue Q/Q Growth	0.00%	0.00%	6.81%	7.03%	4.83%	1.17%
EBITDA Q/Q Growth	0.00%	0.00%	-11.90%	62.42%	29.88%	72.57%
EBIT Q/Q Growth	0.00%	0.00%	-12.12%	54.37%	35.12%	111.87%
NOPAT Q/Q Growth	0.00%	0.00%	-12.12%	53.04%	-44.83%	35.99%
Net Income Q/Q Growth	0.00%	0.00%	-8.95%	70.43%	-40.85%	21.73%
EPS Q/Q Growth	0.00%	0.00%	-9.58%	78.38%	-44.12%	10.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-14.02%	724.82%	76.24%	10.85%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	82.50%	46.34%	27.91%
Invested Capital Q/Q Growth	0.00%	0.00%	115.01%	-1.79%	-16.41%	-19.94%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	87.89%	87.15%	81.92%	87.41%	88.08%	86.93%
EBITDA Margin	2.27%	3.35%	-22.23%	-0.98%	2.14%	2.02%
Operating Margin	2.04%	3.11%	-22.50%	-1.41%	1.25%	0.98%
EBIT Margin	2.04%	3.11%	-22.50%	-1.37%	1.75%	1.61%
Profit (Net Income) Margin	1.01%	3.78%	-19.73%	-0.89%	1.27%	0.98%
Tax Burden Percent	86.81%	131.71%	87.25%	64.93%	72.46%	61.16%
Interest Burden Percent	56.98%	92.45%	100.49%	100.00%	100.00%	100.00%
Effective Tax Rate	13.19%	-31.71%	0.00%	0.00%	27.54%	38.84%
Return on Invested Capital (ROIC)	0.00%	72.14%	-119.45%	-8.03%	7.69%	5.06%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	82.05%	-96.77%	-8.45%	6.05%	3.55%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-29.11%	55.24%	5.54%	-3.96%	-2.42%
Return on Equity (ROE)	0.00%	43.03%	-64.21%	-2.49%	3.73%	2.64%
Cash Return on Invested Capital (CROIC)	0.00%	-127.86%	-173.98%	-13.37%	-16.38%	17.54%
Operating Return on Assets (OROA)	0.00%	7.72%	-42.83%	-2.51%	3.24%	2.61%
Return on Assets (ROA)	0.00%	9.39%	-37.55%	-1.63%	2.35%	1.60%
Return on Common Equity (ROCE)	0.00%	43.95%	-62.02%	-2.38%	3.52%	2.45%
Return on Equity Simple (ROE_SIMPLE)	0.00%	21.06%	-44.66%	-2.42%	3.75%	2.68%
Net Operating Profit after Tax (NOPAT)	14	33	-152	-13	15	10
NOPAT Margin	1.77%	4.09%	-15.75%	-0.99%	0.90%	0.60%
Net Nonoperating Expense Percent (NNEP)	0.00%	-9.91%	-22.68%	0.42%	1.65%	1.51%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-2.58%	2.46%	1.52%
Cost of Revenue to Revenue	12.11%	12.85%	18.08%	12.59%	11.92%	13.07%
SG&A Expenses to Revenue	5.32%	5.39%	26.48%	9.55%	6.61%	7.27%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	85.84%	84.04%	104.42%	88.82%	86.83%	85.95%
Earnings before Interest and Taxes (EBIT)	16	25	-217	-19	29	28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	18	27	-215	-13	36	35
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	3.06	6.45	5.20	4.84	3.69
Price to Tangible Book Value (P/TBV)	0.00	20.29	11.52	8.25	8.63	6.11
Price to Revenue (P/Rev)	0.57	0.55	2.85	1.91	1.64	1.35
Price to Earnings (P/E)	54.40	14.35	0.00	0.00	117.81	163.09
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.84%	6.97%	0.00%	0.00%	0.85%	0.61%
Enterprise Value to Invested Capital (EV/IC)	0.00	4.26	15.36	13.26	10.90	9.90
Enterprise Value to Revenue (EV/Rev)	0.00	0.48	2.58	1.67	1.43	1.10
Enterprise Value to EBITDA (EV/EBITDA)	0.00	14.42	0.00	0.00	66.81	54.16
Enterprise Value to EBIT (EV/EBIT)	0.00	15.54	0.00	0.00	81.85	68.29
Enterprise Value to NOPAT (EV/NOPAT)	0.00	11.80	0.00	0.00	158.77	183.25
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	10.14	45.23	48.05	29.40	17.42
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	52.92
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	0.23	0.07	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.23	0.07	0.00	0.00	0.00
Financial Leverage	0.00	-0.35	-0.57	-0.66	-0.65	-0.68
Leverage Ratio	0.00	2.29	1.71	1.53	1.59	1.65
Compound Leverage Factor	0.00	2.12	1.72	1.53	1.59	1.65
Debt to Total Capital	0.00%	18.98%	6.75%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.49%	0.18%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	18.49%	6.56%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	-1.75%	4.83%	3.84%	7.57%	7.06%
Common Equity to Total Capital	0.00%	82.76%	88.43%	96.16%	92.43%	92.94%
Debt to EBITDA	0.00	1.23	-0.15	0.00	0.00	0.00
Net Debt to EBITDA	0.00	-1.86	1.34	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	1.20	-0.15	0.00	0.00	0.00
Debt to NOPAT	0.00	1.01	-0.21	0.00	0.00	0.00
Net Debt to NOPAT	0.00	-1.52	1.89	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.98	-0.21	0.00	0.00	0.00
Altman Z-Score	0.00	4.26	7.38	7.38	6.02	4.91
Noncontrolling Interest Sharing Ratio	0.00%	-2.16%	3.40%	4.46%	5.85%	7.30%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	0.00	1.29	2.35	2.09	1.81	1.86
Quick Ratio	0.00	1.25	2.30	2.03	1.76	1.80
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-59	-222	-22	-32	36
Operating Cash Flow to CapEx	426.66%	10,234.47%	10,065.45%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	-30.91	-207.19	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	3.53	20.29	51.46	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	2.70	20.09	50.94	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	2.48	1.90	1.83	1.85	1.63
Accounts Receivable Turnover	0.00	8.24	8.93	8.84	6.90	5.72
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	169.73	207.43	343.98	580.54	973.59
Accounts Payable Turnover	0.00	2.68	4.10	3.46	3.57	3.25
Days Sales Outstanding (DSO)	0.00	44.28	40.90	41.30	52.88	63.79
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	136.44	89.03	105.57	102.18	112.41
Cash Conversion Cycle (CCC)	0.00	-92.16	-48.13	-64.27	-49.29	-48.62
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	0.00	93	162	171	218	192
Invested Capital Turnover	0.00	17.63	7.58	8.14	8.52	8.47
Increase / (Decrease) in Invested Capital	0.00	93	69	8.89	47	-26
Enterprise Value (EV)	0.00	394	2,490	2,268	2,375	1,903
Market Capitalization	449	449	2,755	2,596	2,719	2,346
Book Value per Share	$0.00	$1.53	$4.01	$4.37	$4.76	$5.29
Tangible Book Value per Share	$0.00	$0.23	$2.25	$2.75	$2.67	$3.20
Total Capital	0.00	177	483	519	607	683
Total Debt	0.00	34	33	0.00	0.00	0.00
Total Long-Term Debt	0.00	33	32	0.00	0.00	0.00
Net Debt	0.00	-51	-288	-348	-390	-491
Capital Expenditures (CapEx)	5.71	0.38	0.55	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-41	-63	-60	-76	-105
Debt-free Net Working Capital (DFNWC)	0.00	44	257	288	314	386
Net Working Capital (NWC)	0.00	43	256	288	314	386
Net Nonoperating Expense (NNE)	6.00	2.52	38	-1.32	-6.07	-6.66
Net Nonoperating Obligations (NNO)	0.00	-51	-288	-348	-390	-491
Total Depreciation and Amortization (D&A)	1.76	1.96	2.62	5.26	6.53	7.27
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-4.97%	-6.57%	-4.45%	-4.56%	-6.07%
Debt-free Net Working Capital to Revenue	0.00%	5.39%	26.61%	21.21%	18.93%	22.21%
Net Working Capital to Revenue	0.00%	5.28%	26.52%	21.21%	18.93%	22.21%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($1.83)	($0.08)	$0.20	$0.12
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	102.95M	110.70M	116.73M	119.40M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($1.83)	($0.08)	$0.19	$0.11
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	102.95M	110.70M	124.69M	125.61M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	108.17M	115.00M	118.57M	120.51M
Normalized Net Operating Profit after Tax (NOPAT)	14	18	-152	-13	15	10
Normalized NOPAT Margin	1.77%	2.17%	-15.75%	-0.99%	0.90%	0.60%
Pre Tax Income Margin	1.16%	2.87%	-22.61%	-1.37%	1.75%	1.61%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	2.32	13.24	-203.21	0.00	0.00	0.00
NOPAT to Interest Expense	2.02	17.44	-142.25	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	1.50	13.04	-203.72	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	1.19	17.24	-142.76	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	27.08%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-6.66%	0.00%	27.08%	0.00%

This table displays calculated financial ratios and metrics derived from Privia Health Group's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	36.33%	32.36%	23.10%	23.19%	21.69%	20.97%	7.50%	2.17%	4.95%	4.55%	15.62%
EBITDA Growth	72.18%	118.60%	177.51%	376.08%	397.02%	-5.67%	-67.17%	4.17%	-3.81%	121.80%	78.57%
EBIT Growth	64.29%	111.62%	158.15%	248.50%	284.30%	-36.86%	-87.74%	3.44%	-5.37%	269.58%	114.05%
NOPAT Growth	64.29%	182.27%	162.36%	254.92%	221.87%	-93.06%	-86.89%	-48.45%	-25.71%	354.09%	486.00%
Net Income Growth	105.11%	241.71%	135.40%	155.88%	968.71%	-86.21%	-52.26%	-27.00%	-33.05%	130.94%	97.84%
EPS Growth	111.11%	241.67%	137.50%	160.00%	400.00%	-88.24%	-66.67%	-50.00%	-40.00%	50.00%	50.00%
Operating Cash Flow Growth	-74.23%	336.64%	-151.58%	5.40%	39.12%	119.87%	-147.59%	353.10%	47.61%	16.69%	27.39%
Free Cash Flow Firm Growth	-20.81%	102.71%	19.26%	-30.71%	18.99%	-2,145.50%	60.95%	100.06%	128.31%	163.18%	237.42%
Invested Capital Growth	130.93%	5.48%	40.69%	44.85%	49.66%	27.37%	10.76%	1.14%	-7.86%	-11.74%	-11.59%
Revenue Q/Q Growth	2.19%	6.28%	6.00%	7.01%	0.95%	5.64%	-5.80%	1.71%	3.69%	5.25%	4.17%
EBITDA Q/Q Growth	0.44%	198.92%	138.00%	17.78%	7.12%	-68.59%	-17.17%	273.75%	-1.09%	-27.56%	41.95%
EBIT Q/Q Growth	12.88%	149.17%	198.53%	16.12%	8.13%	-83.16%	-42.04%	879.83%	-1.08%	-34.21%	55.28%
NOPAT Q/Q Growth	12.88%	447.97%	-54.76%	12.95%	-31.46%	-80.18%	-14.56%	344.30%	-1.24%	21.12%	10.26%
Net Income Q/Q Growth	104.89%	2,930.22%	-62.00%	-0.66%	-6.57%	-60.89%	31.50%	51.93%	-14.32%	34.92%	12.65%
EPS Q/Q Growth	110.00%	1,600.00%	-64.71%	0.00%	-16.67%	-60.00%	0.00%	50.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	123.71%	80.58%	-145.91%	156.84%	195.27%	185.39%	-151.70%	204.01%	-3.81%	125.61%	-132.17%
Free Cash Flow Firm Q/Q Growth	-83.16%	102.21%	-3,027.27%	-10.41%	-13.52%	44.25%	44.11%	100.17%	52,712.42%	24.43%	21.56%
Invested Capital Q/Q Growth	-0.42%	-1.79%	43.40%	3.29%	2.88%	-16.41%	24.70%	-5.68%	-6.27%	-19.94%	24.91%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.22%	88.11%	88.42%	87.86%	87.94%	88.11%	86.98%	86.48%	87.20%	87.03%	87.60%
EBITDA Margin	-1.00%	0.93%	2.09%	2.29%	2.44%	0.72%	0.64%	2.34%	2.23%	1.54%	2.09%
Operating Margin	-1.33%	0.62%	1.74%	1.69%	1.33%	0.32%	0.20%	1.21%	1.33%	1.14%	1.09%
EBIT Margin	-1.33%	0.62%	1.74%	1.89%	2.02%	0.32%	0.20%	1.91%	1.82%	1.14%	1.70%
Profit (Net Income) Margin	0.16%	4.62%	1.66%	1.54%	1.42%	0.53%	0.74%	1.10%	0.91%	1.16%	1.26%
Tax Burden Percent	-12.96%	495.38%	75.08%	81.58%	70.49%	54.45%	80.27%	57.58%	49.87%	66.90%	74.19%
Interest Burden Percent	93.77%	151.22%	127.00%	100.00%	100.00%	300.56%	462.58%	100.00%	100.00%	152.86%	100.00%
Effective Tax Rate	0.00%	-395.38%	24.92%	18.42%	29.51%	45.55%	19.73%	42.42%	50.13%	33.10%	25.81%
Return on Invested Capital (ROIC)	-9.48%	24.89%	8.89%	9.69%	6.80%	1.50%	1.04%	4.63%	4.54%	6.45%	5.68%
ROIC Less NNEP Spread (ROIC-NNEP)	-10.65%	23.10%	8.43%	9.47%	6.17%	1.07%	0.31%	4.14%	4.25%	6.03%	5.15%
Return on Net Nonoperating Assets (RNNOA)	7.68%	-15.16%	-4.94%	-5.57%	-3.69%	-0.70%	-0.18%	-2.40%	-2.55%	-4.11%	-3.17%
Return on Equity (ROE)	-1.80%	9.74%	3.95%	4.13%	3.11%	0.79%	0.86%	2.22%	1.99%	2.34%	2.51%
Cash Return on Invested Capital (CROIC)	-101.97%	-13.37%	-36.76%	-26.26%	-27.31%	-16.38%	-6.06%	2.15%	11.23%	17.54%	17.50%
Operating Return on Assets (OROA)	-2.35%	1.13%	3.11%	3.38%	3.55%	0.60%	0.35%	3.21%	2.92%	1.85%	2.76%
Return on Assets (ROA)	0.29%	8.48%	2.96%	2.76%	2.50%	0.98%	1.30%	1.85%	1.46%	1.89%	2.05%
Return on Common Equity (ROCE)	-1.77%	9.30%	3.69%	3.86%	2.92%	0.75%	0.80%	2.05%	1.84%	2.17%	2.33%
Return on Equity Simple (ROE_SIMPLE)	-8.68%	0.00%	2.42%	5.74%	6.53%	0.00%	3.07%	2.68%	2.28%	0.00%	3.04%
Net Operating Profit after Tax (NOPAT)	-3.20	11	5.04	5.69	3.90	0.77	0.66	2.94	2.90	3.51	3.87
NOPAT Margin	-0.93%	3.06%	1.31%	1.38%	0.94%	0.18%	0.16%	0.70%	0.66%	0.76%	0.81%
Net Nonoperating Expense Percent (NNEP)	1.16%	1.79%	0.46%	0.22%	0.63%	0.42%	0.72%	0.48%	0.29%	0.42%	0.53%
Return On Investment Capital (ROIC_SIMPLE)	-	2.15%	-	-	-	0.13%	-	-	-	0.51%	0.55%
Cost of Revenue to Revenue	12.78%	11.89%	11.58%	12.14%	12.06%	11.89%	13.02%	13.52%	12.80%	12.97%	12.40%
SG&A Expenses to Revenue	9.40%	7.73%	6.72%	6.49%	6.53%	6.71%	7.74%	6.85%	7.01%	7.47%	6.61%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	88.55%	87.49%	86.68%	86.17%	86.61%	87.79%	86.78%	85.27%	85.87%	85.89%	86.51%
Earnings before Interest and Taxes (EBIT)	-4.57	2.25	6.71	7.80	8.43	1.42	0.82	8.06	7.98	5.25	8.15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-3.42	3.38	8.05	9.49	10	3.19	2.64	9.88	9.77	7.08	10
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.06	5.20	6.19	5.75	4.96	4.84	4.01	3.48	3.54	3.69	4.10
Price to Tangible Book Value (P/TBV)	13.30	8.25	11.32	10.27	8.94	8.63	6.98	5.90	5.85	6.11	6.60
Price to Revenue (P/Rev)	2.99	1.91	2.22	2.00	1.71	1.64	1.37	1.22	1.27	1.35	1.50
Price to Earnings (P/E)	0.00	0.00	195.40	88.83	71.00	117.81	123.43	138.88	169.78	163.09	173.20
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.51%	1.13%	1.41%	0.85%	0.81%	0.72%	0.59%	0.61%	0.58%
Enterprise Value to Invested Capital (EV/IC)	20.07	13.26	11.85	10.85	9.27	10.90	7.39	6.77	7.51	9.90	9.52
Enterprise Value to Revenue (EV/Rev)	2.76	1.67	2.03	1.82	1.53	1.43	1.19	1.02	1.05	1.10	1.27
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	634.60	164.69	88.23	66.81	92.22	86.65	88.53	54.16	57.79
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	241.74	112.46	81.85	136.05	134.70	137.04	68.29	70.98
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	123.69	89.06	158.77	186.97	207.30	236.04	183.25	171.96
Enterprise Value to Operating Cash Flow (EV/OCF)	610.93	48.05	74.29	69.53	52.69	29.40	32.90	19.74	18.28	17.42	19.32
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	316.73	64.11	52.92	51.05
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.72	-0.66	-0.59	-0.59	-0.60	-0.65	-0.56	-0.58	-0.60	-0.68	-0.62
Leverage Ratio	1.61	1.53	1.58	1.62	1.66	1.59	1.62	1.66	1.71	1.65	1.66
Compound Leverage Factor	1.51	2.31	2.00	1.62	1.66	4.78	7.48	1.66	1.71	2.53	1.66
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	4.25%	3.84%	7.77%	8.07%	7.85%	7.57%	7.39%	7.49%	7.14%	7.06%	7.06%
Common Equity to Total Capital	95.75%	96.16%	92.23%	91.93%	92.15%	92.43%	92.61%	92.51%	92.86%	92.94%	92.94%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	8.74	7.46	7.68	6.66	5.75	5.92	5.15	4.61	4.39	4.84	5.18
Noncontrolling Interest Sharing Ratio	1.71%	4.46%	6.52%	6.55%	6.22%	5.85%	7.57%	7.76%	7.47%	7.30%	7.21%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.90	2.09	1.90	1.82	1.77	1.81	1.80	1.81	1.78	1.86	1.88
Quick Ratio	1.85	2.03	1.85	1.78	1.73	1.76	1.73	1.76	1.73	1.80	1.82
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-102	2.25	-66	-73	-83	-46	-26	0.04	23	29	35
Operating Cash Flow to CapEx	100,906.25%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.76	1.83	1.79	1.79	1.76	1.85	1.77	1.68	1.61	1.63	1.63
Accounts Receivable Turnover	7.35	8.84	6.69	5.65	5.30	6.90	5.56	4.92	4.52	5.72	4.90
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	316.73	343.98	390.26	440.95	505.22	580.54	657.20	733.58	846.94	973.59	1,180.37
Accounts Payable Turnover	6.78	3.46	3.85	4.08	3.71	3.57	4.27	3.90	3.66	3.25	3.91
Days Sales Outstanding (DSO)	49.63	41.30	54.54	64.64	68.84	52.88	65.67	74.25	80.71	63.79	74.45
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	53.85	105.57	94.80	89.39	98.30	102.18	85.48	93.59	99.68	112.41	93.25
Cash Conversion Cycle (CCC)	-4.21	-64.27	-40.26	-24.76	-29.46	-49.29	-19.81	-19.34	-18.97	-48.62	-18.80
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	174	171	245	253	261	218	272	256	240	192	240
Invested Capital Turnover	10.16	8.14	6.81	7.04	7.27	8.52	6.53	6.65	6.85	8.47	7.04
Increase / (Decrease) in Invested Capital	99	8.89	71	78	86	47	26	2.89	-20	-26	-31
Enterprise Value (EV)	3,496	2,268	2,907	2,748	2,415	2,375	2,008	1,735	1,803	1,903	2,286
Market Capitalization	3,792	2,596	3,175	3,020	2,699	2,719	2,313	2,074	2,177	2,346	2,706
Book Value per Share	$4.22	$4.37	$4.46	$4.54	$4.64	$4.76	$4.87	$4.99	$5.14	$5.29	$5.47
Tangible Book Value per Share	$2.56	$2.75	$2.44	$2.54	$2.57	$2.67	$2.80	$2.94	$3.11	$3.20	$3.40
Total Capital	491	519	557	571	591	607	623	644	662	683	710
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-317	-348	-311	-318	-330	-390	-351	-387	-422	-491	-469
Capital Expenditures (CapEx)	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-42	-60	-32	-22	-27	-76	-27	-37	-48	-105	-54
Debt-free Net Working Capital (DFNWC)	275	288	279	296	303	314	324	350	374	386	416
Net Working Capital (NWC)	275	288	279	296	303	314	324	350	374	386	416
Net Nonoperating Expense (NNE)	-3.76	-5.71	-1.36	-0.67	-2.04	-1.55	-2.40	-1.71	-1.08	-1.86	-2.17
Net Nonoperating Obligations (NNO)	-317	-348	-311	-318	-330	-390	-351	-387	-422	-491	-469
Total Depreciation and Amortization (D&A)	1.15	1.14	1.34	1.69	1.73	1.77	1.82	1.82	1.80	1.83	1.90
Debt-free, Cash-free Net Working Capital to Revenue	-3.30%	-4.45%	-2.25%	-1.49%	-1.70%	-4.56%	-1.59%	-2.20%	-2.78%	-6.07%	-2.98%
Debt-free Net Working Capital to Revenue	21.70%	21.21%	19.53%	19.61%	19.19%	18.93%	19.23%	20.65%	21.81%	22.21%	23.08%
Net Working Capital to Revenue	21.70%	21.21%	19.53%	19.61%	19.19%	18.93%	19.23%	20.65%	21.81%	22.21%	23.08%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.01	$0.17	$0.06	$0.06	$0.05	$0.03	$0.03	$0.03	$0.03	$0.03	$0.03
Adjusted Weighted Average Basic Shares Outstanding	111.59M	110.70M	115.01M	116.16M	117.60M	116.73M	118.51M	119.30M	119.66M	119.40M	120.62M
Adjusted Diluted Earnings per Share	$0.01	$0.17	$0.06	$0.06	$0.05	$0.02	$0.02	$0.03	$0.03	$0.03	$0.03
Adjusted Weighted Average Diluted Shares Outstanding	124.85M	110.70M	124.33M	124.57M	124.92M	124.69M	125.05M	125.32M	125.75M	125.61M	127.75M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	114.30M	115.00M	115.66M	117.36M	118.06M	118.57M	119.32M	119.56M	120.00M	120.51M	121.92M
Normalized Net Operating Profit after Tax (NOPAT)	-3.20	1.57	5.04	5.69	3.90	0.77	0.66	2.94	4.07	3.51	3.87
Normalized NOPAT Margin	-0.93%	0.43%	1.31%	1.38%	0.94%	0.18%	0.16%	0.70%	0.93%	0.76%	0.81%
Pre Tax Income Margin	-1.25%	0.93%	2.21%	1.89%	2.02%	0.97%	0.92%	1.91%	1.82%	1.74%	1.70%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	18.88%	16.02%	27.08%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	18.88%	16.02%	27.08%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Privia Health Group (NASDAQ: PRVA) has demonstrated consistent growth in operating revenue over the last four years, increasing from approximately $342.9 million in Q3 2022 to $480.1 million in Q1 2025. This steady top-line growth reflects expanding operations and market presence.

The company's gross profit has correspondingly improved, rising from about $299.1 million in Q3 2022 to $420.6 million in Q1 2025, indicating relatively stable cost of revenue management despite revenue growth.

Operating expenses have increased significantly, particularly due to notable "Other Operating Expenses" which rose to $374.8 million in Q1 2025 from lower levels in previous years, indicating either growing operational scale or higher operating costs.

Despite increasing expenses, Privia managed to post positive operating income each quarter, with Q1 2025 showing an operating income of roughly $5.2 million compared to a loss in Q3 2022. This marks a clear improvement in operational efficiency and profitability.

Net income attributable to common shareholders gradually improved from a lower base in 2022 to $4.22 million in Q1 2025, with earnings per share steady at about $0.03 diluted in recent quarters.

Cash flow from operating activities has shown volatility, including significant negative outflows in Q1 of recent years (e.g., negative $24.1 million in Q1 2025 and negative $33.1 million in Q1 2024), primarily driven by changes in operating assets and liabilities. However, positive cash flow quarters like Q4 2024 ($74.8 million) indicate potential for cash generation.

Investing activities have generally involved outflows related to acquisitions and minor investing activities, with no acquisitions reported in Q1 2025 but prior quarters showing investments up to $24.9 million (Q1 2023).

Financing activities mainly reflect modest inflows, such as $2.24 million in Q1 2025, indicating some ongoing capital raising or other financing actions.

The balance sheet shows a solid liquidity position, with cash and equivalents rising from $316.9 million in Q3 2022 to $469.3 million in Q1 2025. Total assets also increased steadily to $1.18 billion by Q1 2025.

Total liabilities increased but remain manageable relative to total equity, with equity and noncontrolling interests growing to about $709.5 million in Q1 2025 from $491.1 million in Q4 2022, reflecting retained earnings and capital contributions.

Operating revenue has grown steadily from $342.9 million in Q3 2022 to $480.1 million in Q1 2025, indicating strong business expansion.
Consistent positive operating income since early 2024 shows improving operational efficiency.
Gross profit margin remains robust, reflecting control over cost of revenue.
Increasing cash and equivalents to $469.3 million in Q1 2025 improves financial flexibility.
Growth in total equity and controlled liabilities indicate strengthening financial stability.
Significant volatility in operating cash flow, with large negative changes in some quarters, indicates working capital management challenges.
Large “Other Operating Expenses” component in recent quarters needs monitoring to assess sustainability and cause.
Diluted EPS stable but modest at $0.03 in recent quarters, suggesting limited earnings growth despite revenue gains.
Negative operating cash flow in Q1 2025 (-$24.1 million) and prior Q1 periods points to potential cash burn periods requiring capital support.
Acquisition-related cash outflows in prior quarters may pressure cash reserves if not accretive to earnings swiftly.

Overall, Privia Health Group has shown solid revenue growth and profitability improvements over the past several years, with strengthening liquidity and equity positions. However, cash flow management and rising operating expenses, especially “Other Operating Expenses,” remain areas that investors should watch as they could impact future earnings consistency and cash sustainability.

10/25/25 03:58 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Privia Health Group's Financials

When does Privia Health Group's fiscal year end?

According to the most recent income statement we have on file, Privia Health Group's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Privia Health Group's net income changed over the last 5 years?

Privia Health Group's net income appears to be on a downward trend, with a most recent value of $17.04 million in 2024, rising from $7.95 million in 2019. The previous period was $21.03 million in 2023. View Privia Health Group's forecast to see where analysts expect Privia Health Group to go next.

What is Privia Health Group's operating income?

Privia Health Group's total operating income in 2024 was $16.98 million, based on the following breakdown:

Total Gross Profit: $1.51 billion
Total Operating Expenses: $1.49 billion

How has Privia Health Group's revenue changed over the last 5 years?

Over the last 5 years, Privia Health Group's total revenue changed from $786.36 million in 2019 to $1.74 billion in 2024, a change of 120.8%.

How much debt does Privia Health Group have?

Privia Health Group's total liabilities were at $452.34 million at the end of 2024, a 15.2% increase from 2023, and a 144.1% increase since 2020.

How much cash does Privia Health Group have?

In the past 4 years, Privia Health Group's cash and equivalents has ranged from $84.63 million in 2020 to $491.15 million in 2024, and is currently $491.15 million as of their latest financial filing in 2024.

How has Privia Health Group's book value per share changed over the last 5 years?

Over the last 5 years, Privia Health Group's book value per share changed from 0.00 in 2019 to 5.29 in 2024, a change of 529.3%.

Related Companies

This page (NASDAQ:PRVA) was last updated on 10/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Privia Health Group (PRVA) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Privia Health Group's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Privia Health Group (PRVA) Financials

Annual Income Statements for Privia Health Group

Quarterly Income Statements for Privia Health Group

Annual Cash Flow Statements for Privia Health Group

Quarterly Cash Flow Statements for Privia Health Group

Annual Balance Sheets for Privia Health Group

Quarterly Balance Sheets for Privia Health Group

Annual Metrics And Ratios for Privia Health Group

Quarterly Metrics And Ratios for Privia Health Group

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Privia Health Group's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools